Literature DB >> 34233141

Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis.

Jacob Louis Marott1, Truls Sylvan Ingebrigtsen2, Yunus Çolak3, Jørgen Vestbo4,5, Peter Lange6,7.   

Abstract

RATIONALE: Natural history of Preserved Ratio Impaired Spirometry (PRISm), often defined as FEV1/FVC≥lower limit of normal and FEV1<80% of predicted value, is not well-described.
OBJECTIVE: To investigate natural history and long-term prognosis of PRISm trajectories: persistent PRISm trajectory (individuals with PRISm both as young and as middle-aged); normal-to-PRISm trajectory (individuals developing PRISm from normal spirometry in young adulthood); and PRISm-to-normal trajectory (individuals recovering from PRISm in young adulthood by normalizing spirometry while middle-aged).
METHODS: We followed 1160 individuals aged 20-40 years from the Copenhagen City Heart Study from 1976-83 until 2001-03 to determine their lung function trajectory: 72 had persistent PRISm trajectory, 76 normal-to-PRISm trajectory, 155 PRISm-to-normal trajectory, and 857 had normal trajectory. From 2001-03 until 2018, we determined risk of cardiopulmonary disease and death.
MEASUREMENTS AND MAIN RESULTS: We recorded 198 admissions for heart disease, 143 for pneumonia, and 64 for COPD, and 171 deaths. Compared to individuals with normal trajectory, hazards ratios for individuals with persistent PRISm trajectory were 1.55 (95% CI, 0.91-2.65) for heart disease admission, 2.86 (1.70-4.83) for pneumonia admission, 6.57 (3.41-12.66) for COPD admission, and 3.68 (2.38-5.68) for all-cause mortality. Corresponding hazards ratios for individuals with normal-to-PRISm trajectory were 1.91 (1.24-2.95), 2.74 (1.70-4.42), 6.03 (3.41-10.64), and 2.96 (1.94-4.51), respectively. Prognosis of individuals with PRISm-to-normal trajectory did not differ from those with normal trajectory.
CONCLUSIONS: PRISm in middle-aged individuals is associated with increased risk of cardiopulmonary disease and all-cause mortality, but individuals who recover from PRISm during their adult life are no longer at increased risk.

Entities:  

Keywords:  Morbidity; Mortality; Preserved Ratio Impaired Spirometry (PRISm); Trajectories

Year:  2021        PMID: 34233141     DOI: 10.1164/rccm.202102-0517OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  5 in total

1.  Journal Club-Respiratory Impairment With A Preserved Spirometric Ratio.

Authors:  Takudzwa Mkorombindo; Ron Balkissoon
Journal:  Chronic Obstr Pulm Dis       Date:  2022-01-27

2.  Journal Club: Impaired Ventilatory Efficiency and Exercise Intolerance in Former/Current Smokers With Dyspnea Disproportionate to Their Lung Function: Pathophysiological Insights Gained Through Cardiopulmonary Exercise Testing.

Authors:  Ron Balkissoon; Takudzwa Mkorombindo
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

3.  Clinical and Immunological Markers of Pulmonary Impairment Among People With HIV in India.

Authors:  Anurima Baidya; Shashikala Sangle; Ivan Marbaniang; Vandana Kulkarni; Prasad Deshpande; Smita Nimkar; Amol Chavan; Sonali Salvi; Rahul Lokhande; Dileep Kadam; Amita Gupta; Vidya Mave; Akshay N Gupte
Journal:  Open Forum Infect Dis       Date:  2022-05-11       Impact factor: 4.423

4.  Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults.

Authors:  Emily S Wan; Pallavi Balte; Joseph E Schwartz; Surya P Bhatt; Patricia A Cassano; David Couper; Martha L Daviglus; Mark T Dransfield; Sina A Gharib; David R Jacobs; Ravi Kalhan; Stephanie J London; Ana Navas-Acien; George T O'Connor; Jason L Sanders; Benjamin M Smith; Wendy White; Sachin Yende; Elizabeth C Oelsner
Journal:  JAMA       Date:  2021-12-14       Impact factor: 157.335

5.  Impaired exercise outcomes with significant bronchodilator responsiveness in children with prematurity-associated obstructive lung disease.

Authors:  Michael Cousins; Kylie Hart; E Mark Williams; Sailesh Kotecha
Journal:  Pediatr Pulmonol       Date:  2022-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.